Form 8-K - Current report:
SEC Accession No. 0001615219-25-000040
Filing Date
2025-03-28
Accepted
2025-03-28 16:30:33
Documents
14
Period of Report
2025-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K flks-20250326.htm   iXBRL 8-K 39884
2 EX-2.1 projectsierra-conformedame.htm EX-2.1 59502
  Complete submission text file 0001615219-25-000040.txt   233240

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT flks-20250326.xsd EX-101.SCH 1807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT flks-20250326_lab.xml EX-101.LAB 21689
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT flks-20250326_pre.xml EX-101.PRE 12543
16 EXTRACTED XBRL INSTANCE DOCUMENT flks-20250326_htm.xml XML 2724
Mailing Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 346-772-0346
Salarius Pharmaceuticals, Inc. (Filer) CIK: 0001615219 (see all company filings)

EIN.: 465087339 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36812 | Film No.: 25786854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)